Verastem, Inc. (VSTM): Price and Financial Metrics


Verastem, Inc. (VSTM)

Today's Latest Price: $2.45 USD

0.03 (1.24%)

Updated Jan 15 4:00pm

Add VSTM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 483 in Biotech

See all "A" rated Strong Buy stocks

VSTM Stock Summary

  • With a year-over-year growth in debt of -57.06%, Verastem Inc's debt growth rate surpasses only 5.23% of about US stocks.
  • Revenue growth over the past 12 months for Verastem Inc comes in at 508.85%, a number that bests 98.56% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for VSTM comes in at -22.78% -- higher than that of merely 11.83% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Verastem Inc are VREX, CEMI, SUPN, PAR, and WISA.
  • Visit VSTM's SEC page to see the company's official filings. To visit the company's web site, go to www.verastem.com.

VSTM Stock Price Chart Interactive Chart >

Price chart for VSTM

VSTM Price/Volume Stats

Current price $2.45 52-week high $4.67
Prev. close $2.42 52-week low $1.08
Day low $2.38 Volume 3,881,400
Day high $2.52 Avg. volume 3,194,780
50-day MA $2.00 Dividend yield N/A
200-day MA $1.78 Market Cap 415.95M

Verastem, Inc. (VSTM) Company Bio


Verastem, Inc. focuses on discovering and developing drugs for the treatment of cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. The company was founded in 2010 and is based in Needham, Massachusetts.


VSTM Latest News Stream


Event/Time News Detail
Loading, please wait...

VSTM Latest Social Stream


Loading social stream, please wait...

View Full VSTM Social Stream

Latest VSTM News From Around the Web

Below are the latest news stories about Verastem Inc that investors may wish to consider to help them evaluate VSTM as an investment opportunity.

Verastem Oncology: Targeting The RAS Pathway To Develop New Cancer Medicines

Summary Verastem Oncology (VSTM) is an early-stage biotechnology company developing new medicines for cancer patients. The company was founded in 2010 originally to develop new drugs targeting cancer stem cells. With Verastem centered around two key papers - The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells and Identification...

Numenor Capital on Seeking Alpha | January 12, 2021

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the grant of options to purchase 86,250 shares of its common stock and the grant of 43,125 restricted stock units (RSUs) to five new employees. The awards were granted as an inducement material to the employees' acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to $2.20 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on January 4, 2021. The stock options and RSUs that were granted to the five new employees will vest at a rate of twenty-five percent (25%) on the one year anniversary of the...

Yahoo | January 7, 2021

Verastem Oncology Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced the appointment of industry veteran Frank Neumann, M.D., Ph.D., as Chief Medical Officer to oversee the Company’s clinical and regulatory strategy and Medical Affairs team.

Yahoo | January 6, 2021

Verastem Oncology to Present at the H.C. Wainwright BioConnect 2021 Conference

Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced that the Company will present at the virtual H.C. Wainwright BioConnect 2021 Conference. The fireside chat will be made available for on-demand listening beginning Monday, January 11, 2021 at 6:00 a.m. EST.

Yahoo | January 5, 2021

Who Has Been Buying Verastem, Inc. (NASDAQ:VSTM) Shares?

We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are also...

Yahoo | December 29, 2020

Read More 'VSTM' Stories Here

VSTM Price Returns

1-mo 11.36%
3-mo 100.82%
6-mo 77.54%
1-year N/A
3-year -21.47%
5-year 67.81%
YTD 15.02%
2020 58.96%
2019 -60.12%
2018 9.45%
2017 174.11%
2016 -39.78%

Continue Researching VSTM

Here are a few links from around the web to help you further your research on Verastem Inc's stock as an investment opportunity:

Verastem Inc (VSTM) Stock Price | Nasdaq
Verastem Inc (VSTM) Stock Quote, History and News - Yahoo Finance
Verastem Inc (VSTM) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8754 seconds.